N-Cadherin block against prostate cancer
University of California, Los Angeles researchers have shown that mAbs targeting the cell surface protein N-cadherin can inhibit prostate cancer growth, metastasis and progression to castration-resistant disease.1 If Emtx Therapeutics Inc.exercises its option to license and develop N-cadherin-specific antibodies for use in cancer, it could have a candidate ready for clinical testing in two to three years.
Although androgen ablation is one of the mainstays for treating prostate cancer, many patients still progress to castration-resistant disease in 12-18 months.2 Nearly all pathways that are associated with the transition from androgen-dependent to castration-resistant disease include reactivation of signaling pathways that involve the androgen receptor (AR).3,4...